The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study
Research payments
$6,703,559
Through program year 2020, $6,703,559 in research payments was reported against The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study, across 29 payments, paid by Sanofi US Services Inc..
- Paid by
- Sanofi US Services Inc.
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
2 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2020 | Research | $323,649 | 27 |
| 2019 | Research | $6,379,910 | 2 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- David Nathan Boston, MA Named on 5 payments
- Richard Bergenstal Minneapolis, MN Named on 2 payments
- Adrian Vella Rochester, MN Named on 1 payment
- Rose Gubitosi-Klug Cleveland, OH Named on 1 payment
- Ryan Miller Baltimore, MD Named on 1 payment
- Arti Bhan Detroit, MI Named on 1 payment
- John Malone Tampa, FL Named on 1 payment
- William Sivitz Iowa City, IA Named on 1 payment
- Naina Sinha New York, NY Named on 1 payment
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.